Beam Therapeutics' pipeline progress remains slow, with BEAM-101 still recruiting and CAR-T programs discontinued to reduce cash burn. Gene therapy markets targeted by Beam, such as SCD and AATD, are ...
Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 and Risto-cel in 2026. BEAM-302's "in vivo" gene editing for AATD achieved a ...
Beam Therapeutics has presented the first clinical data on its base editing technology. All four sickle cell disease patients in the efficacy cohort had fetal hemoglobin levels above Beam’s target—and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results